JP2007511516A - 薬品送達ビヒクル中の賦形剤 - Google Patents

薬品送達ビヒクル中の賦形剤 Download PDF

Info

Publication number
JP2007511516A
JP2007511516A JP2006539843A JP2006539843A JP2007511516A JP 2007511516 A JP2007511516 A JP 2007511516A JP 2006539843 A JP2006539843 A JP 2006539843A JP 2006539843 A JP2006539843 A JP 2006539843A JP 2007511516 A JP2007511516 A JP 2007511516A
Authority
JP
Japan
Prior art keywords
composition
polymer
beneficial agent
solvent
magnesium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006539843A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007511516A5 (https=
Inventor
チエン，グオフア
プリーブ，デイビツド・テイ
Original Assignee
アルザ・コーポレーシヨン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルザ・コーポレーシヨン filed Critical アルザ・コーポレーシヨン
Publication of JP2007511516A publication Critical patent/JP2007511516A/ja
Publication of JP2007511516A5 publication Critical patent/JP2007511516A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2006539843A 2003-11-14 2004-11-12 薬品送達ビヒクル中の賦形剤 Pending JP2007511516A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51997203P 2003-11-14 2003-11-14
US10/985,116 US20050281879A1 (en) 2003-11-14 2004-11-10 Excipients in drug delivery vehicles
PCT/US2004/037606 WO2005048989A1 (en) 2003-11-14 2004-11-12 Excipients in drug delivery vehicles

Publications (2)

Publication Number Publication Date
JP2007511516A true JP2007511516A (ja) 2007-05-10
JP2007511516A5 JP2007511516A5 (https=) 2007-07-26

Family

ID=34623114

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006539843A Pending JP2007511516A (ja) 2003-11-14 2004-11-12 薬品送達ビヒクル中の賦形剤

Country Status (14)

Country Link
US (1) US20050281879A1 (https=)
EP (1) EP1691785A4 (https=)
JP (1) JP2007511516A (https=)
KR (1) KR20060125748A (https=)
AR (1) AR046842A1 (https=)
AU (2) AU2004291077A1 (https=)
BR (1) BRPI0416032A (https=)
CA (1) CA2545913C (https=)
IL (1) IL175601A0 (https=)
MX (1) MXPA06005464A (https=)
NO (1) NO20062781L (https=)
PE (1) PE20050494A1 (https=)
TW (1) TW200524631A (https=)
WO (1) WO2005048989A1 (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE418323T1 (de) * 2002-11-06 2009-01-15 Alza Corp Depot-formulierungen mit verzögerter freisetzung
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20050106214A1 (en) * 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
EP1899462B1 (en) * 2005-07-02 2011-03-09 Arecor Limited Stable aqueous systems comprising proteins
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
AU2013202598B2 (en) * 2005-09-30 2016-06-09 Durect Corporation Sustained release small molecule drug formulation
US7407922B2 (en) 2005-10-13 2008-08-05 S.C. Johnson & Son, Inc. Deodorizing compositions
US7261742B2 (en) 2005-10-13 2007-08-28 S.C. Johnson & Son, Inc. Method of deodorizing a textile
MX2008009125A (es) * 2006-01-18 2008-10-23 Qps Llc Composiciones farmaceuticas con estabilidad mejorada.
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
EP2049081B1 (en) 2006-08-09 2012-11-14 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
HRP20130259T1 (hr) 2007-04-23 2013-04-30 Intarcia Therapeutics, Inc. Suspenzijske formulacije inzulinotropnih peptida i njihove uporabe
DK2167039T3 (en) 2007-05-18 2017-01-09 Durect Corp Improved depot formulations
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
US20110027172A1 (en) * 2007-12-10 2011-02-03 Zhuang Wang Drug delivery system for pharmaceuticals and radiation
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
US8956642B2 (en) * 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
US20100016808A1 (en) * 2008-07-17 2010-01-21 Bioform Medical, Inc. Thin-Walled Delivery System
ES2344674B1 (es) * 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
SMT201700583T1 (it) 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2841105A4 (en) * 2012-03-30 2016-12-21 Nanunanu Ltd MAGNESIUM PHOSPHATE GELS
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HK1211232A1 (en) 2012-12-21 2016-05-20 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
HK1220628A1 (zh) 2013-03-11 2017-05-12 Durect Corporation 包含高粘度液体载体的可注射控制释放组合物
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
NZ731309A (en) 2014-11-07 2022-02-25 Indivior Uk Ltd Buprenorphine dosing regimens
TWI731853B (zh) * 2015-03-18 2021-07-01 日商參天製藥股份有限公司 徐放性醫藥組成物及其安定化方法
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
EP3318280A4 (en) * 2015-07-01 2018-08-22 Santen Pharmaceutical Co., Ltd Depot preparation containing citric acid ester
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
CN105295310A (zh) * 2015-11-11 2016-02-03 苏州国泰科技发展有限公司 一种绿色环保型增塑剂
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
JP2023515918A (ja) 2020-01-13 2023-04-17 デュレクト コーポレーション 不純物が低減された徐放性薬物送達システム及び関連の方法
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001509146A (ja) * 1996-12-20 2001-07-10 アルザ コーポレイション ゲル組成物および方法
JP2002532210A (ja) * 1998-12-18 2002-10-02 アンジオソニックス インコーポレイテッド 超音波により癌および他の細胞増殖性疾病を阻止および治療する方法
WO2003041684A2 (en) * 2001-11-14 2003-05-22 Alza Corporation Injectable depot compositions and uses thereof
WO2003041757A2 (en) * 2001-11-14 2003-05-22 Alza Corporation Catheter injectable depot compositions and uses thereof
JP2003526624A (ja) * 1999-04-20 2003-09-09 サヴィファーム インコーポレイテッド 肝臓病の予防及び治療に有用なアミノイミダゾールカルボキサミド塩
JP2005514350A (ja) * 2001-11-14 2005-05-19 アルザ・コーポレーション 注入可能なデポー組成物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US630200A (en) * 1899-03-13 1899-08-01 Draper Co Warp-stop-motion mechanism.
US4443340A (en) * 1981-10-09 1984-04-17 Betz Laboratories, Inc. Control of iron induced fouling in water systems
US4985404A (en) * 1984-10-04 1991-01-15 Monsanto Company Prolonged release of biologically active polypeptides
US4853218A (en) * 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
AU668384B2 (en) * 1992-03-12 1996-05-02 Alkermes Controlled Therapeutics, Inc. Controlled release ACTH containing microspheres
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5711968A (en) * 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US20030035845A1 (en) * 1992-06-11 2003-02-20 Zale Stephen E. Composition for sustained release of non-aggregated erythropoietin
US5242910A (en) * 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
WO1994012158A1 (en) * 1992-12-02 1994-06-09 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
ATE317690T1 (de) * 1994-04-08 2006-03-15 Qlt Usa Inc Flüssige zusammensetzungen zur arzneistoffabgabe
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5801012A (en) * 1996-09-17 1998-09-01 Northwestern University Methods and compositions for generating angiostatin
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
JP3077635B2 (ja) * 1997-06-20 2000-08-14 日本電気株式会社 高速無線アクセス装置
US20030211974A1 (en) * 2000-03-21 2003-11-13 Brodbeck Kevin J. Gel composition and methods
WO2002089849A1 (en) * 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
US20040001889A1 (en) * 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US20050106214A1 (en) * 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001509146A (ja) * 1996-12-20 2001-07-10 アルザ コーポレイション ゲル組成物および方法
JP2002532210A (ja) * 1998-12-18 2002-10-02 アンジオソニックス インコーポレイテッド 超音波により癌および他の細胞増殖性疾病を阻止および治療する方法
JP2003526624A (ja) * 1999-04-20 2003-09-09 サヴィファーム インコーポレイテッド 肝臓病の予防及び治療に有用なアミノイミダゾールカルボキサミド塩
WO2003041684A2 (en) * 2001-11-14 2003-05-22 Alza Corporation Injectable depot compositions and uses thereof
WO2003041757A2 (en) * 2001-11-14 2003-05-22 Alza Corporation Catheter injectable depot compositions and uses thereof
JP2005514350A (ja) * 2001-11-14 2005-05-19 アルザ・コーポレーション 注入可能なデポー組成物

Also Published As

Publication number Publication date
AR046842A1 (es) 2005-12-28
CA2545913A1 (en) 2005-06-02
EP1691785A1 (en) 2006-08-23
WO2005048989A1 (en) 2005-06-02
EP1691785A4 (en) 2012-08-29
AU2011201972A1 (en) 2011-05-19
CA2545913C (en) 2013-12-31
BRPI0416032A (pt) 2007-01-02
US20050281879A1 (en) 2005-12-22
KR20060125748A (ko) 2006-12-06
MXPA06005464A (es) 2006-08-11
IL175601A0 (en) 2006-09-05
AU2011201972B2 (en) 2013-06-13
AU2004291077A1 (en) 2005-06-02
PE20050494A1 (es) 2005-08-24
TW200524631A (en) 2005-08-01
NO20062781L (no) 2006-08-14

Similar Documents

Publication Publication Date Title
JP4916887B2 (ja) 薬品送達ビヒクル中の賦形剤
JP2007511516A (ja) 薬品送達ビヒクル中の賦形剤
US7368126B2 (en) Controlled release depot formulations
JP5325152B2 (ja) 注入可能なデポー組成物およびそれらの使用
JP5170935B2 (ja) 注入可能なデポー組成物
JP4639400B2 (ja) 注入可能な多モードポリマーのデポ組成物及びその使用
JP2006503004A (ja) 射出可能なデポ組成物及びその使用
CN1889929B (zh) 药物递送媒介物中的赋形剂
CN1886153A (zh) 药物递送媒介物中的赋形剂
HK1082412B (en) Short duration depot formulations
HK1082412A1 (en) Short duration depot formulations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070604

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071023

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110322

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110622

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110622

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110629

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110722

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110722

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110729

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110822

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110822

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110829

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120110